|
|
|
| Expression and Correlation of CerbB-2, EGFR, bcl-2, P53 and Ki-67 in Gastric Carcinoma |
| HAN Lu, et al |
| Chengde Medical College, Hebei Chengde 067000, China |
|
|
|
|
Abstract Objective: To analyze the expression and correlation of C-erbB-2, EGFR, bcl-2, P53 and Ki-67 in gastric cancer, and to provide the theoretical basis for the prognosis and targeted therapy of gastric cancer. Methods: The immunohistochemical staining results of C-erbB-2, EGFR, Bcl-2, P53 and Ki-67 in 193 patients with gastric cancer were analyzed retrospectively. Results: C-erbB-2 and EGFR were associated with invasion depth and lymph node metastasis (P<0.05), but not with tumor differentiation (P>0.05); P53 was associated with lymph node metastasis and differentiation (P <0.05), but not with depth (P>0.05); Ki-67 was associated with invasion depth, Ki-67 was associated with invasion depth, lymph node metasis and tumor differentiation (P<0.05). At the same time, the results showed that the indicators were associated with age and sex of patients with gastric cancer (P>0.05). There was a positive correlation between C-erbB-2 and EGFR, Ki-67 and bcl-2, EGFR and Ki-67; bcl-2 was negatively correlated with P53; there was no correlation between the other indexes. Conclusion: The expression of C-erbB-2, EGFR, bcl-2, P53 and Ki-67 in gastric carcinoma is related to the clinicopathological features. The combined detection is important for the prognosis and targeted therapy of gastric cancer.
|
|
|
|
|
|
[1] Jemal A,Siegel R,Ward E,et al.Cancer statistics,2009[J].CA Cancer Clin,2009,59(4):225~249.
[2] 史振贵.消化性溃疡与胃癌的关系分析分析[J].吉林医学,2011,32(3):542.
[3] 张帆,杨兴吴,李连宏,等.胃癌中EGFR的表达与临床、病理、预后及多药耐药蛋白P170、TOPOⅡ、GST-π表达的关系[J].临床与实验病理学杂志,2013,29(10):1060~1064,1068.
[4] 朱玉侠,赵明星,姜登鸽,等.抑癌基因P53、凋亡基因Bcl-2、促凋亡基因Bax在胃癌及癌前病变中的表达[J].胃肠病学和肝病学杂志,2016,25(9):1040~1043.
[5] 朱艳丽,杜井峰,杨丽,等.Rhoc、Ki-67和Bcl-2在胃癌发生发展中的表达及其相关性研究[J].中国病案,2013,(4):60~62.
[6] 朱瑞雪,时永全,张连峰.NDRG2和Bcl-2在胃癌组织中的表达及意义[J].细胞与分子免疫学杂志,2015,31(4):516~519.
[7] 崔颖,刘亮,王琳,等.Rhoc、Ki-67、bcl-2在胃癌发生发展中的表达及相关性[J].2011,31(2):228~229.
[8] 陈斌,罗荣城,崔斐,等.胃癌HER/neu基因表达与预后的相关性[J].南方医科大学学报,2006,26(3):344.
[9] 袁志超,陈健,杨树成.胃癌P53、nm23、CerbB-2的表达与其预后关系分析[J].中国医药指南,2016,14(32):20~21.
[10] Selcukbiricik F, Erdamar S, Buyukunal E, et al. Is her-2 status in the primary tumor correlated with matched lymph node metastases in patients with gastric cancer undergoing curative gastrectomy[J].Asian Pac Cancer Prev, 2014,15(24):10607~10611.
[11] Arslan D, Uysal M. Her-2 positive gastric cancer presented with thrombocytopenia and skin involvement: a case report[J].Case Rep Oncol Med, 2014,20(14):194636.
[12] Takeda S. Tetrahydrocannabinol targeting estrogen receptor signaling: the possible mechanism of action coupled with endocrine disruption[J].Biol Pharm Bull, 2014,37(9): 1435~1438.
[13] 吴霞,李代强.ALK和EGFR蛋白在非小细胞肺癌中的表达及意义[J].国际病理科学与临床杂志,2013,33(2):120~124.
[14] 赵文江,周喜元,王志强,等.Bcl-2和Hrk及细胞周期素E在胃癌组织中的表达及其意义[J].中国全科医学,2012,15(24):2790~2793.
[15] 王艳良.胃癌患者血清Bcl-2的表达水平及意义[J].中国继续医学教育,2015,7(6):171~172.
[16] 陈实,陈映波,李元方.p53蛋白及PCNA的表达与胃癌预后的关系[J].广东医学,2009,30(4):570~572.
[17] 高文华,付勇,谷翠华,等.EGFR、CEA、P53在胃癌组织中的表达及意义[J].现代肿瘤医学,2015(13):1874~1878.
[18] Ogata DC, Marcondes CA, Tuon FF, et al. Sperfical papillary urothelial neoplasmas of the bladder(PTA E PT1): correlation of expression of p53, Ki-67 and CK20 with histologic grade, recurrence and tumor progression[J].Rev Col Bras Cir, 2012,39(5):394~400.
[19] Vilar E, Salazar R, Perez-Garcia J, et al. Chemotherapy and role of the proliferation marker Ki-67 in digestive neuroendocrine tumors[J].Endocr Relat cancer,2007,14(2):221~232.
[20] 秦娟,晏伟,王三喜,等.Ki67、p53及EGFR在胃癌组织中的表达水平及临床意义[J].实用癌症杂志,2017,32(1):37~39,43.
[21] 凌斌勋,陈环球,徐新宇,等.C-erbB-2和EGFR在胃癌中的表达[J].江苏医药,2009,35(1):17~19. |
|
|
|
2018, Vol. 24 
